All sponsors

Shenzhen Salubris Pharmaceuticals Co., Ltd.

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS10
PHASE 3 / 2-30
RECRUITING3
READOUTS ≤12 MONTHS5
Open Shenzhen Salubris Pharmaceuticals Co., Ltd. on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
SAL-0951 tablets 4mg
NCT06737081
P2RecruitingAnemia602025-12-31
SAL0120 1mg
NCT07716618
P2Active, not recruitingChronic Kidney Disease3202026-05-27
SAL056 56.5μg
NCT07579936
P2RecruitingPostmenopausal Women With Osteoporosis2002026-07-30
GW906
NCT07835971
P2Active, not recruitingHypertension3192026-09-15
SAL0137 Dose 1
NCT07729475
P2Not yet recruitingElevated Lipoprotein(a)1202026-12-12
SAL0140
NCT07654140
P2RecruitingUncontrolled Hypertension2522027-03-01
SAL0140 Tablets
NCT07646535
P2Not yet recruitingPrimary Aldosteronism502027-04-01
GW906
NCT07835984
P2Not yet recruitingHypertension5602027-10
SAL0140 Tablets
NCT07647133
P2Not yet recruitingChronic Kidney Disease2492027-10-08
SAL0150 dose 1
NCT07923357
P2Not yet recruitingType 2 Diabetes Mellitus (T2DM); Type 2 Diabetes3642027-11-30